Which has better earnings and valuation, PRAX or BHVN?

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Praxis Precision Medicines N/A N/A -$303.27M -$13.37 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is PRAX or BHVN more profitable?

Praxis Precision Medicines' return on equity of -43.02% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Praxis Precision Medicines N/A -43.02% -40.22% Biohaven N/A -866.46% -137.99%

Does the media favor PRAX or BHVN?

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 1 mentions for Biohaven. Praxis Precision Medicines' average media sentiment score of 0.59 beat Biohaven's score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BHVN or CRNX?

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 1 mentions for Biohaven. Crinetics Pharmaceuticals' average media sentiment score of 0.32 beat Biohaven's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BHVN or TGTX?

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A TG Therapeutics $616.29M 13.63 $447.18M $2.86 19.19

Is BHVN or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% TG Therapeutics 65.95% 88.73% 43.44%

Does the media refer more to BHVN or TGTX?

In the previous week, TG Therapeutics had 17 more articles in the media than Biohaven. MarketBeat recorded 18 mentions for TG Therapeutics and 1 mentions for Biohaven. TG Therapeutics' average media sentiment score of 0.37 beat Biohaven's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, IBRX or BHVN?

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmunityBio $140.98M 57.06 -$351.40M -$0.85 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is IBRX or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets ImmunityBio -606.15% N/A -59.53% Biohaven N/A -866.46% -137.99%

Does the media favor IBRX or BHVN?

In the previous week, ImmunityBio had 8 more articles in the media than Biohaven. MarketBeat recorded 9 mentions for ImmunityBio and 1 mentions for Biohaven. ImmunityBio's average media sentiment score of 0.88 beat Biohaven's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, BHVN or SYRE?

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$5.67 N/A Spyre Therapeutics N/A N/A -$155.20M -$2.08 N/A

Is BHVN or SYRE more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -866.46% -137.99% Spyre Therapeutics N/A -42.88% -27.76%

Does the media refer more to BHVN or SYRE?

In the previous week, Spyre Therapeutics had 5 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Spyre Therapeutics and 1 mentions for Biohaven. Spyre Therapeutics' average media sentiment score of 0.62 beat Biohaven's score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biohaven (BHVN) Competitors

$15.45 +1.28 (+9.06%)

Closing price 07/17/2026 03:59 PM Eastern

Extended Trading

$15.39 -0.06 (-0.41%)

As of 07/17/2026 07:59 PM Eastern

Compare

BHVN vs. PRAX, CRNX, TGTX, IBRX, and SYRE

Should you buy Biohaven stock or one of its competitors? MarketBeat compares Biohaven with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biohaven include Praxis Precision Medicines (PRAX), Crinetics Pharmaceuticals (CRNX), TG Therapeutics (TGTX), ImmunityBio (IBRX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Biohaven compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

Praxis Precision Medicines has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$303.27M	-$13.37	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Praxis Precision Medicines' return on equity of -43.02% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-43.02%	-40.22%
Biohaven	N/A	-866.46%	-137.99%

In the previous week, Praxis Precision Medicines had 3 more articles in the media than Biohaven. MarketBeat recorded 4 mentions for Praxis Precision Medicines and 1 mentions for Biohaven. Praxis Precision Medicines' average media sentiment score of 0.59 beat Biohaven's score of 0.00 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines currently has a consensus target price of $563.50, suggesting a potential upside of 79.22%. Biohaven has a consensus target price of $21.63, suggesting a potential upside of 39.93%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe Praxis Precision Medicines is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

Summary

Praxis Precision Medicines beats Biohaven on 10 of the 14 factors compared between the two stocks.

How does Biohaven compare to Crinetics Pharmaceuticals?

Biohaven (NYSE:BHVN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Biohaven has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Biohaven has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

In the previous week, Crinetics Pharmaceuticals had 4 more articles in the media than Biohaven. MarketBeat recorded 5 mentions for Crinetics Pharmaceuticals and 1 mentions for Biohaven. Crinetics Pharmaceuticals' average media sentiment score of 0.32 beat Biohaven's score of 0.00 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crinetics Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Biohaven shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals has higher revenue and earnings than Biohaven. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Crinetics Pharmaceuticals	$18.07M	489.36	-$465.32M	-$5.13	N/A

Biohaven presently has a consensus price target of $21.63, suggesting a potential upside of 39.93%. Crinetics Pharmaceuticals has a consensus price target of $78.27, suggesting a potential downside of 6.66%. Given Biohaven's stronger consensus rating and higher possible upside, analysts clearly believe Biohaven is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67
Crinetics Pharmaceuticals	1 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Biohaven and Crinetics Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Biohaven compare to TG Therapeutics?

Biohaven (NYSE:BHVN) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Biohaven presently has a consensus target price of $21.63, suggesting a potential upside of 39.93%. TG Therapeutics has a consensus target price of $53.33, suggesting a potential downside of 2.80%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

88.8% of Biohaven shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 13.8% of Biohaven shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 88.73% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
TG Therapeutics	65.95%	88.73%	43.44%

In the previous week, TG Therapeutics had 17 more articles in the media than Biohaven. MarketBeat recorded 18 mentions for TG Therapeutics and 1 mentions for Biohaven. TG Therapeutics' average media sentiment score of 0.37 beat Biohaven's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
TG Therapeutics	$616.29M	13.63	$447.18M	$2.86	19.19

Biohaven has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Summary

TG Therapeutics beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Biohaven compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Biohaven (NYSE:BHVN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, ImmunityBio had 8 more articles in the media than Biohaven. MarketBeat recorded 9 mentions for ImmunityBio and 1 mentions for Biohaven. ImmunityBio's average media sentiment score of 0.88 beat Biohaven's score of 0.00 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biohaven has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Biohaven	N/A	-866.46%	-137.99%

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 84.90%. Biohaven has a consensus price target of $21.63, indicating a potential upside of 39.93%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ImmunityBio has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

ImmunityBio has higher revenue and earnings than Biohaven. ImmunityBio is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$140.98M	57.06	-$351.40M	-$0.85	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

Summary

ImmunityBio beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Biohaven compare to Spyre Therapeutics?

Biohaven (NYSE:BHVN) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A

Biohaven presently has a consensus target price of $21.63, indicating a potential upside of 39.93%. Spyre Therapeutics has a consensus target price of $101.42, indicating a potential upside of 1.18%. Given Biohaven's higher probable upside, equities research analysts clearly believe Biohaven is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.67
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Biohaven has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.02, meaning that its stock price is 202% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 5 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Spyre Therapeutics and 1 mentions for Biohaven. Spyre Therapeutics' average media sentiment score of 0.62 beat Biohaven's score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics' return on equity of -42.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-866.46%	-137.99%
Spyre Therapeutics	N/A	-42.88%	-27.76%

Summary

Spyre Therapeutics beats Biohaven on 10 of the 14 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$2.32B	$3.69B	$6.86B	$23.39B
Dividend Yield	N/A	2.17%	2.67%	4.16%
P/E Ratio	-2.73	21.03	27.25	30.95
Price / Sales	N/A	177.66	517.83	165.09
Price / Cash	N/A	154.08	52.99	31.95
Price / Book	39.63	8.26	10.69	4.76
Net Income	-$738.82M	$23.83M	$3.59B	$1.07B
7 Day Performance	-0.92%	-3.47%	-2.20%	-0.01%
1 Month Performance	13.94%	2.69%	1.63%	1.08%
1 Year Performance	10.07%	45.93%	25.64%	16.70%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	2.9419 of 5 stars	$15.45 +9.1%	$21.63 +39.9%	+10.1%	$2.32B	N/A	N/A	239
PRAX Praxis Precision Medicines	3.2562 of 5 stars	$314.56 -3.2%	$563.50 +79.1%	+483.9%	$9.06B	$8.55M	N/A	110
CRNX Crinetics Pharmaceuticals	1.3299 of 5 stars	$83.67 +0.1%	$78.27 -6.5%	+169.6%	$8.81B	$7.70M	N/A	210
TGTX TG Therapeutics	3.0642 of 5 stars	$55.01 -3.7%	$53.33 -3.0%	+44.7%	$8.74B	$616.29M	19.23	290	Analyst Revision
IBRX ImmunityBio	3.299 of 5 stars	$7.79 -5.2%	$14.20 +82.3%	+179.3%	$8.61B	$113.29M	N/A	590	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors

BHVN vs. PRAX, CRNX, TGTX, IBRX, and SYRE

How does Biohaven compare to Praxis Precision Medicines?

Summary

How does Biohaven compare to Crinetics Pharmaceuticals?

Summary

How does Biohaven compare to TG Therapeutics?

Summary

How does Biohaven compare to ImmunityBio?

Summary

How does Biohaven compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biohaven (BHVN) Competitors

BHVN vs. PRAX, CRNX, TGTX, IBRX, and SYRE

How does Biohaven compare to Praxis Precision Medicines?

Which has more risk and volatility, PRAX or BHVN?

Which has better earnings and valuation, PRAX or BHVN?

Do institutionals & insiders believe in PRAX or BHVN?

Is PRAX or BHVN more profitable?

Does the media favor PRAX or BHVN?

Do analysts rate PRAX or BHVN?

Summary

How does Biohaven compare to Crinetics Pharmaceuticals?

Which has more volatility and risk, BHVN or CRNX?

Is BHVN or CRNX more profitable?

Does the media refer more to BHVN or CRNX?

Do institutionals & insiders hold more shares of BHVN or CRNX?

Which has stronger valuation & earnings, BHVN or CRNX?

Do analysts prefer BHVN or CRNX?

Summary

How does Biohaven compare to TG Therapeutics?

Do analysts recommend BHVN or TGTX?

Do institutionals and insiders have more ownership in BHVN or TGTX?

Is BHVN or TGTX more profitable?

Does the media refer more to BHVN or TGTX?

Which has stronger earnings & valuation, BHVN or TGTX?

Which has more volatility and risk, BHVN or TGTX?

Summary

How does Biohaven compare to ImmunityBio?

Does the media favor IBRX or BHVN?

Is IBRX or BHVN more profitable?

Do analysts rate IBRX or BHVN?

Do institutionals & insiders have more ownership in IBRX or BHVN?

Which has more risk and volatility, IBRX or BHVN?

Which has better earnings and valuation, IBRX or BHVN?

Summary

How does Biohaven compare to Spyre Therapeutics?

Do institutionals and insiders believe in BHVN or SYRE?

Which has preferable earnings & valuation, BHVN or SYRE?

Do analysts recommend BHVN or SYRE?

Which has more risk and volatility, BHVN or SYRE?

Does the media refer more to BHVN or SYRE?

Is BHVN or SYRE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHVN vs. The Competition

Biohaven Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools